Cell Medica Targeting Next CAR-T Wave: Solid Tumor Anticancers

Cell Medica has just raised a large Series C from UK institutional investors to explore the use of novel cell-based immunotherapies in solid tumors, a “new chapter” for this class of therapeutic agents.